Want to see GB:VAL full AI Analyst Report?
VAL Stock Chart & Stats
0.16 p
<0.01 p(1.56%)
At close: 4:00 PM EDT
0.16 p
<0.01 p(1.56%)
Day’s Range― - ―
52-Week Range0.12 p - 0.60 p
Previous CloseN/A
Volume993.58K
Average Volume (3M)4.33M
Market Cap
£1.65M
Enterprise Value-0.11 p
Total Cash (Recent Filing)£970.56K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Jun 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume5,742,896
30 Day Avg. Volume4,327,052
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt limits interest obligations and reduces leverage-related financial risk. This gives ValiRx greater flexibility than a highly indebted developer when allocating scarce capital, although its ability to fund operations remains constrained by continuing cash losses.
Focused Therapeutic PipelineA defined focus on oncology and women’s health can concentrate scientific resources and support specialist expertise rather than dispersing investment across unrelated areas. Progress in selected candidates could create meaningful strategic value if development milestones are achieved.
Partnering-oriented Development ModelUsing collaboration partners to advance selected assets may help ValiRx access development capabilities and share the burden of progressing drug candidates. This model can improve the scalability of a small specialist biotechnology company if partnerships generate sustained asset progress.
Bears Say
Declining And Minimal RevenueRevenue remains extremely small relative to the company’s operating cost base and declined materially year over year. This indicates that commercial or partnered income is not yet providing a durable funding engine, leaving ValiRx dependent on future asset progress or external financing.
Persistent UnprofitabilityRecurring negative gross profit, operating losses, and net losses show that ValiRx has not reached an economically self-sustaining stage. Continued losses can consume shareholder capital and make future profitability dependent on successful development, commercialization, or partnering outcomes.
Structural Cash Burn And Shrinking AssetsPersistent negative operating and free cash flow means the business is not funding itself from operations. The concurrent reduction in equity and total assets signals erosion of financial capacity, increasing the importance of securing outside funding or monetizing development assets.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.12 p and its highest was 0.60 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £1.65M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 09, 2027 which is in 252 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Sep 15, 2026. The company reported -0.001 p earnings per share for the quarter.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―